πŸ‡ΊπŸ‡Έ FDA
Patent

US 10610520

Heterocyclic compound

granted A61KA61K31/407A61K31/4184

Quick answer

US patent 10610520 (Heterocyclic compound) held by Takeda Pharmaceutical Company Limited expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/407, A61K31/4184, A61K31/4188, A61K31/422